Clinical Trial Update: Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) [Phase 2]

View source ↗

Summary

Phase 2 study MK-4280A-010 evaluating favezelimab coformulated with pembrolizumab in selected solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Endometrial Cancer

Drugs mentioned

• Favezelimab (favezelimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED